Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7460372 | 0.83 | HTR6 (0.56) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL16316761 | 0.81 | CA2 (0.53) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL14087505 | 0.79 | GAB1 (0.51) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL4472092 | 0.78 | CA2 (0.53) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL14519932 | 0.78 | LOX (0.51) | HTR6VDR | |
| SCHEMBL6927501 | 0.78 | HTR6 (0.50) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL6927505 | 0.78 | CA2 (0.71) | CA2 | |
| SCHEMBL3017949 | 0.78 | GAB1 (0.50) | CA2HTR6GAB1MMP8MMP3 | |
| Hydrochloric Acid SCHEMBL28825306 | 0.77 | CA2 (0.51) | CA2HTR6GAB1MMP8MMP3 | |
| SCHEMBL15880546 | 0.74 | CA2 (0.52) | CA2HTR6GAB1MMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA2 3978/4885HTR6 3454/4885GAB1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.